These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 18338430)

  • 21. FDA notifications. Tentative approval to Aptivus for combination ART.
    AIDS Alert; 2007 Dec; 22(12):144. PubMed ID: 18411486
    [No Abstract]   [Full Text] [Related]  

  • 22. Tipranavir (Aptivus): approval cautiously recommended.
    James JS
    AIDS Treat News; 2005 May; (412):2-3. PubMed ID: 16047408
    [TBL] [Abstract][Full Text] [Related]  

  • 23. European Commission grants full approval for Aptivus.
    AIDS Patient Care STDS; 2008 May; 22(5):438. PubMed ID: 18521974
    [No Abstract]   [Full Text] [Related]  

  • 24. Salvage therapy update.
    Emery C
    Surviv News (Atlanta Ga); 2005; 16(6):8. PubMed ID: 16388538
    [No Abstract]   [Full Text] [Related]  

  • 25. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials.
    Hicks CB; Cahn P; Cooper DA; Walmsley SL; Katlama C; Clotet B; Lazzarin A; Johnson MA; Neubacher D; Mayers D; Valdez H;
    Lancet; 2006 Aug; 368(9534):466-75. PubMed ID: 16890833
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Porphyria cutanea tarda in an HIV-1-infected patient after the initiation of tipranavir/ritonavir: case report.
    Celesia BM; Onorante A; Nunnari G; Mughini MT; Mavilla S; Massimino SD; Russo R
    AIDS; 2007 Jul; 21(11):1495-6. PubMed ID: 17589203
    [No Abstract]   [Full Text] [Related]  

  • 27. [Non-peptide protease inhibitor in phase III study. Tipranavir--control of multidrug resistant viruses].
    MMW Fortschr Med; 2003 Apr; 145 Spec No 1():78-9. PubMed ID: 15011599
    [No Abstract]   [Full Text] [Related]  

  • 28. Tipranavir: the first nonpeptidic protease inhibitor.
    Cheonis N
    BETA; 2004; 16(2):15-7. PubMed ID: 15104065
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug interactions of tipranavir, a new HIV protease inhibitor.
    Morello J; Rodriguez-Novoa S; Jimenez-Nacher I; Soriano V
    Drug Metab Lett; 2007 Jan; 1(1):81-4. PubMed ID: 19356024
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tipranavir.
    Flexner C; Bate G; Kirkpatrick P
    Nat Rev Drug Discov; 2005 Dec; 4(12):955-6. PubMed ID: 16370086
    [No Abstract]   [Full Text] [Related]  

  • 31. Efficacy, safety and tolerability of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescents.
    Salazar JC; Cahn P; Yogev R; Negra MD; Castelli-Gattinara G; Fortuny C; Flynn PM; Giaquinto C; Ruan PK; Smith ME; Mikl J; Jelaska A;
    AIDS; 2008 Sep; 22(14):1789-98. PubMed ID: 18753862
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Boehringer drug for resistant HIV approved.
    AIDS Read; 2005 Aug; 15(8):379, 391. PubMed ID: 16110551
    [No Abstract]   [Full Text] [Related]  

  • 33. [Perspectives: hope for therapy experienced patients. Tipranavir shows superior effectiveness with comparable safety].
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():44-5. PubMed ID: 16385873
    [No Abstract]   [Full Text] [Related]  

  • 34. Tipranavir demonstrates potent and durable treatment response in HIV-positive women.
    AIDS Patient Care STDS; 2007 Aug; 21(8):602-3. PubMed ID: 17907309
    [No Abstract]   [Full Text] [Related]  

  • 35. [New treatment options for HIV-infected patients].
    Wehr A
    Dtsch Med Wochenschr; 2004 May; 129(19):1093. PubMed ID: 15174468
    [No Abstract]   [Full Text] [Related]  

  • 36. A lame duck, a dark horse, and a goat.
    Huff B
    GMHC Treat Issues; 2005; 19(5-6):4-5. PubMed ID: 16193576
    [No Abstract]   [Full Text] [Related]  

  • 37. Meeting notes from ICAAC. Ritonavir-boosted tipranavir proves beneficial in treatment-experienced patients.
    Feinberg J
    AIDS Clin Care; 2005 Jan; 17(1):5-6. PubMed ID: 15717371
    [No Abstract]   [Full Text] [Related]  

  • 38. Atazanavir: new indication. First-line treatment: fewer gastrointestinal disorders but more cases of jaundice and a risk of torsades de pointes.
    Prescrire Int; 2009 Jun; 18(101):104. PubMed ID: 19637415
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A king in the CASTLE? Optimum initial HIV protease inhibitor.
    Torti C; Frank I
    Lancet; 2008 Aug; 372(9639):604-6. PubMed ID: 18722849
    [No Abstract]   [Full Text] [Related]  

  • 40. Drug interactions. Kaletra and atazanavir.
    TreatmentUpdate; 2006; 18(3):7-8. PubMed ID: 17211919
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.